BMT IN MULTIPLE MYELOMA — PROGNOSTIC FACTORS

[1]  P. Ljungman,et al.  Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. , 1994, Leukemia & lymphoma.

[2]  P. Ljungman,et al.  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.

[3]  G. Gahrton,et al.  Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. , 1993, Bone marrow transplantation.

[4]  A A Rimm,et al.  Outcome after allogeneic bone marrow transplant for leukemia in older adults. , 1993, JAMA.

[5]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. , 1993, Blood.

[6]  Lust,et al.  Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.

[7]  F. Appelbaum,et al.  Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Klein,et al.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.

[9]  A. Barrett,et al.  HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome , 1992, British journal of haematology.

[10]  B. Mazières,et al.  Intensive combined therapy for previously untreated aggressive myeloma. , 1992, Blood.

[11]  E. Thiel,et al.  Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. , 1991, Annals of internal medicine.

[12]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[13]  M. Gobbi,et al.  Prognostic variables and clinical staging in multiple myeloma. , 1989, Blood.

[14]  E. Montserrat,et al.  A new prognostic system for multiple myeloma based on easily available parameters , 1989, British journal of haematology.

[15]  H. Strander,et al.  Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS , 1989, European journal of haematology.

[16]  A. Gallamini,et al.  Allogeneic bone marrow transplantation in multiple myeloma. , 1987, Acta haematologica.

[17]  J. Sporn,et al.  Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. , 1986, Seminars in oncology.

[18]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.

[19]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[20]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.